Skip to main content
. 2015 May 1;43(11):5307–5317. doi: 10.1093/nar/gkv419

Figure 4.

Figure 4.

Clinical significance of SASE. (A) Age of the samples that have signatures of accelerated somatic evolution in the promoters of BCL2 are significantly higher relative to other lymphoma samples in the cohort. (B) Age of the samples that have signatures of accelerated somatic evolution in the promoters of MYC are significantly lower relative to other lymphoma samples in the cohort. (C) The samples with SASE in the promoters of BCL2, TCL1A and BTG2 are more likely to have more incidence of partial remission or relapse, compared to other samples in the lymphoma cohort (P-value < 0.05 in each case). (D) SASE in RBM5 promoter was significantly associated with poor survival in the melanoma cohort.